Kodiak Sciences Inc. (NASDAQ:KOD) and Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of the two firms.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kodiak Sciences Inc.||N/A||0.00||38.35M||-1.07||0.00|
|Diffusion Pharmaceuticals Inc.||N/A||0.00||19.60M||-0.45||0.00|
Demonstrates Kodiak Sciences Inc. and Diffusion Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 hightlights the return on equity, return on assets and net margins of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|Kodiak Sciences Inc.||0.00%||0%||0%|
|Diffusion Pharmaceuticals Inc.||0.00%||-79.1%||-69.4%|
Kodiak Sciences Inc.’s Current Ratio is 2.3 while its Quick Ratio is 2.3. On the competitive side is, Diffusion Pharmaceuticals Inc. which has a 12.2 Current Ratio and a 12.2 Quick Ratio. Diffusion Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Kodiak Sciences Inc.
Insider and Institutional Ownership
The shares of both Kodiak Sciences Inc. and Diffusion Pharmaceuticals Inc. are owned by institutional investors at 13.6% and 10.7% respectively. 11.6% are Kodiak Sciences Inc.’s share held by insiders. On the other hand, insiders held about 3.37% of Diffusion Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Kodiak Sciences Inc.||-8.65%||-4.2%||0%||0%||0%||-16.83%|
|Diffusion Pharmaceuticals Inc.||-28.54%||-48.11%||-51.34%||-64.27%||-85.5%||-83.04%|
For the past year Kodiak Sciences Inc.’s stock price has smaller decline than Diffusion Pharmaceuticals Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.